1. Home
  2. HBCP vs NGNE Comparison

HBCP vs NGNE Comparison

Compare HBCP & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home Bancorp Inc.

HBCP

Home Bancorp Inc.

N/A

Current Price

$60.47

Market Cap

434.2M

Sector

Finance

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.93

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBCP
NGNE
Founded
1908
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.2M
327.8M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
HBCP
NGNE
Price
$60.47
$20.93
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$63.50
$38.50
AVG Volume (30 Days)
22.7K
211.4K
Earning Date
01-26-2026
11-13-2025
Dividend Yield
2.06%
N/A
EPS Growth
24.56
N/A
EPS
5.62
N/A
Revenue
$145,087,000.00
N/A
Revenue This Year
$2.60
N/A
Revenue Next Year
$3.27
N/A
P/E Ratio
$10.74
N/A
Revenue Growth
11.42
N/A
52 Week Low
$39.59
$6.88
52 Week High
$61.07
$37.27

Technical Indicators

Market Signals
Indicator
HBCP
NGNE
Relative Strength Index (RSI) 76.05 44.81
Support Level $56.41 $19.65
Resistance Level $60.72 $23.00
Average True Range (ATR) 0.93 1.44
MACD 0.50 0.28
Stochastic Oscillator 95.72 54.90

Price Performance

Historical Comparison
HBCP
NGNE

About HBCP Home Bancorp Inc.

Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: